영화메디칼

비상장계속사업자

younghwamedical

김영화

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

영화메디칼

Business Reg. No. 6098606159 · CEO 김영화

I.Investment Overview

Target영화메디칼 (6098606159)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명영화메디칼
영문명younghwamedical
대표자김영화
사업자등록번호6098606159
법인등록번호1942110200395
설립일2012.05.22

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW10.6202110.7202210.6202317.7202418.92025
영업이익100M KRW2.620214.12022420235.420246.22025
순이익100M KRW0.320211.120220.720231.220242.22025
Item20252024202320222021
자산총계193.9억원189.2억원188억원186.9억원186억원
부채총계115.9억원113.4억원113.4억원112.9억원113.1억원
자본총계78억원75.8억원74.6억원73.9억원72.9억원
매출액18.9억원17.7억원10.6억원10.7억원10.6억원
영업이익6.2억원5.4억원4억원4.1억원2.6억원
순이익2.2억원1.2억원6,722만원1.1억원2,594만원

VI.Financial Ratios

FY2025 basis

33.06%

영업이익률

11.71%

순이익률

1.14%

ROA

2.83%

ROE

148.62%

부채비율

40.22%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

영화메디칼 투심보고서 | Alpha Lenz